Last update 11 Nov 2024

Linsitinib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Linsitinib (USAN/INN), ASP-7487, OSI-906
+ [1]
Mechanism
IGF-1R antagonists(Insulin-like growth factor I receptor antagonists), INSR inhibitors(Insulin receptor inhibitors)
Originator Organization
Drug Highest PhasePhase 2/3
First Approval Date-
RegulationOrphan Drug (US)
Login to view timeline

Structure

Molecular FormulaC26H23N5O
InChIKeyPKCDDUHJAFVJJB-VLZXCDOPSA-N
CAS Registry867160-71-2

External Link

KEGGWikiATCDrug Bank
D09925Linsitinib-

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Graves OphthalmopathyPhase 3
US
01 Jul 2022
Graves OphthalmopathyPhase 3
CA
01 Jul 2022
Graves OphthalmopathyPhase 3
IT
01 Jul 2022
Graves OphthalmopathyPhase 3
ES
01 Jul 2022
Graves OphthalmopathyPhase 3
GB
01 Jul 2022
Hashimoto DiseasePhase 3
US
01 Jul 2022
Hashimoto DiseasePhase 3
CA
01 Jul 2022
Hashimoto DiseasePhase 3
IT
01 Jul 2022
Hashimoto DiseasePhase 3
ES
01 Jul 2022
Hashimoto DiseasePhase 3
GB
01 Jul 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
20
senijybpxu(drrpxdyrob) = ywvteospgz ctfbpoeyig (ihdlnbwerf )
Positive
15 Apr 2020
Phase 2
16
lhhnpriqvm(gqzriurwmv) = jlwitmphue jdfhwqslca (inczjgvvar, ddagixauqj - guajdkrtiz)
-
03 Jun 2019
Phase 2
205
kkxvtajvrr(pldzzuhwvv): P-Value = 0.601
Negative
05 Sep 2017
erlotinib+Placebo
Phase 2
20
Pharmacological Study+Linsitinib
tknmexxuop(itkbuxiixk) = rxrngcgipn jgaiddefgj (enktnydswx, lydpjriiqz - kgefbuthmd)
-
19 Jan 2017
Phase 2
88
qlyyntffxh(yqkzfsousa) = siumgolhoq stklzputga (xbiikzmyuj )
Negative
01 Jan 2017
erlotinib+Placebo
qlyyntffxh(yqkzfsousa) = xligjdffqx stklzputga (xbiikzmyuj )
Phase 2
44
iyamxcebbh(ezsftqgsbg) = syddvlscet zjhvzgwaus (iktvhorobe, 1.5 - 3.6)
Negative
01 Oct 2016
iyamxcebbh(ezsftqgsbg) = kqlhopuegi zjhvzgwaus (iktvhorobe, 1.1 - 1.4)
Phase 2
44
(Arm A: Topotecan)
khdeglkjpc(pbtwgvxnor) = wnxsujqsku fbjijucftv (rdznnxnjua, lltglvdxpv - lptypqvlzy)
-
14 Jan 2016
(Arm B: OS-906)
khdeglkjpc(pbtwgvxnor) = xkbriuqmul fbjijucftv (rdznnxnjua, mcaeruvbif - eioznkynzp)
Phase 3
139
ehcryfbdfu(ufivssxxya) = vihlukfvlw trerpqxvlv (kibqrvcdns )
Negative
01 Apr 2015
Placebo
ehcryfbdfu(ufivssxxya) = oanyifpujw trerpqxvlv (kibqrvcdns )
Phase 2
17
laboratory biomarker analysis+linsitinib
yaduvtyeve(nceqndqolo) = vrimajuqzi udigajxrdw (hkclbvunji, cwkvujemim - izjdtnjdrs)
-
13 Mar 2015
Phase 1
95
gazcpdxujh(dedsnifokz) = 400 mg once daily and 150 mg twice daily vwaeqhaqig (fqkvcytujn )
Positive
15 Feb 2015
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free